Pfizer's 7% Yield Under Scrutiny as Patent Cliff Looms
Pfizer has distributed $14.6 billion to shareholders over the last six quarters, but a looming patent cliff and elevated payout ratios raise questions about the sustainability of its 7% yield.
Pfizer has returned $14.6 billion to shareholders over the past six quarters, supporting a 7% dividend yield that dwarfs the 1.5% average for the pharmaceutical sector and the 1% yield of the broader S&P 500. The company distributed $9.8 billion in dividends in 2025, followed by another $4.8 billion in the first half of 2026.
This massive cash outflow arrives just as the company faces a severe patent cliff that threatens its primary revenue drivers. Patent protection for key blockbuster drugs is set to expire in rapid succession. The oncology treatment Ibrance loses exclusivity in 2027, followed by cardiovascular medications Eliquis and Vyndaqel in 2028. When these patents lapse, cheaper generic alternatives will enter the market, typically triggering sharp declines in branded drug revenue.
The fundamental challenge for Pfizer is the absence of major new drugs ready to replace the anticipated revenue shortfall. While patent expirations operate on a predictable calendar, drug research and development does not. Pharmaceutical companies must constantly fund R&D to replenish their pipelines, but Pfizer's current trajectory suggests new therapies may not arrive in time to counter the generic competition.
This pipeline gap was highlighted by a very public setback in 2025, when the company was forced to drop a GLP-1 drug candidate. The failure underscores the execution risk involved in relying on R&D to bail out a maturing portfolio.
For income-focused investors, the critical question is whether the dividend is safe. The financial metrics paint a picture of stress. At the end of the first quarter of 2026, Pfizer's trailing 12-month dividend payout ratio stood at over 130%, a level that traditionally alarms income investors. Because dividends are a cash expense, the cash flow statement provides a more accurate measure of sustainability. On a cash basis, the payout ratio is slightly more reassuring at 103%.
Pfizer has stated that the dividend remains a priority. However, a cash payout ratio above 100% means the company is paying out more cash to shareholders than it generates from operations. To maintain the 7% yield without cutting the dividend, Pfizer must either dramatically accelerate cash flow from new products or rely on balance sheet leverage.
